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578Objective: The objectives of our study are to (1) describe our experience with endobronchial ultrasound-guided
fine-needle aspiration of mediastinal lymph nodes and (2) illustrate how thoracic surgeons facile with ultrasound-
guided fine-needle aspiration have the potential to streamline patient care.
Methods: We performed a retrospective review of all patients within our prospectively maintained database who
underwent endobronchial ultrasound-guided fine-needle aspiration of mediastinal lymph nodes by thoracic sur-
geons at the University of Minnesota from September 1, 2006, to April 15, 2009. We included patients in our
analysis if (1) their malignancy diagnosis was based on immediate endobronchial ultrasound-guided fine-needle
aspiration cytology or (2) they underwent a confirmatory procedure (ie, mediastinoscopy or thoracoscopy) that
sampled the same mediastinal lymph node stations biopsied by endobronchial ultrasound-guided fine-needle as-
piration to verify normal, benign, or nondiagnostic endobronchial ultrasound-guided fine-needle aspiration find-
ings. We also collected data on additional diagnostic or therapeutic procedures performed in the same anesthesia
setting as endobronchial ultrasound-guided fine-needle aspiration.
Results: Over the study period, 192 patients underwent endobronchial ultrasound-guided fine-needle aspiration;
98 patients met our inclusion criteria. We achieved a sensitivity of 87.9%, specificity of 97.4%, and diagnostic
accuracy of 91.7%. For patients undergoing lung cancer staging, we sampled a mean of 3.0  0.9 mediastinal
lymph node stations. Half of our patients underwent an additional diagnostic or therapeutic procedure at the
time of endobronchial ultrasound-guided fine-needle aspiration.
Conclusion: Thoracic surgeons who perform endobronchial ultrasound-guided fine-needle aspiration can achieve
excellent sensitivity, specificity, and diagnostic accuracy while adhering to sound oncologic principles. Endo-
bronchial ultrasound-guided fine-needle aspiration adds to the thoracic surgeon’s unique capacity to expedite
a diagnostic workup and treatment, thereby streamlining patient care. (J Thorac Cardiovasc Surg 2010;139:
578-83)Real-time endobronchial ultrasound-guided fine-needle
aspiration (EBUS-FNA) is a safe, simple, precise, minimally
invasive method to diagnose mediastinal pathology and
stage the mediastinum in thoracic malignancies.1 Although
EBUS-FNA of mediastinal lymph nodes (MLNs) has
a reported diagnostic performance that is comparable to
mediastinoscopy,1-15 the available data have significant lim-
itations. Concerns about EBUS-FNA of MLNs include the
following: (1) The negative predictive value (NPV) for
EBUS-FNA of MLNs may be poor (as low as 11%) and
may vary more widely than for mediastinoscopy;16 (2) pub-
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The Journal of Thoracic and Cardiovascular Surgnal staging for non–small cell lung cancer (NSCLC) report
sampling on average only 1.5 central MLN stations per pa-
tient;7,17 and (3) to date, no reports have addressed perform-
ing additional diagnostic or therapeutic procedures in the
same anesthesia setting as EBUS-FNA, in a manner akin
to the current use of mediastinoscopy.
The aim of our study is to report our results with EBUS-
FNA of MLNs by addressing diagnostic performance and
thorough staging. We also evaluated the use of additional
procedures in the same anesthesia setting as EBUS-FNA
in an attempt to demonstrate that thoracic surgeons facile
in EBUS-FNA have the ability to streamline patient care.PATIENTS AND METHODS
Patients
The University of Minnesota Institutional Review Board approved this
retrospective review of our prospectively maintained database and waived
the need to obtain informed consent for each patient. We studied the charts
of all consecutive patients who underwent EBUS-FNA at our institution for
evaluation of mediastinal lymphadenopathy or staging of thoracic malig-
nancy from September 1, 2006 (the first EBUS-FNA at the University of
Minnesota), to April 15, 2009. We included patients in our analysis if (1)
their malignancy diagnosis was based on immediate EBUS-transbronchial
needle aspiration cytology or (2) they underwent a confirmatory procedure
(ie, mediastinoscopy, thoracoscopy) that sampled the same MLN stations
biopsied by EBUS-FNA to verify normal, benign, or nondiagnosticery c March 2010
Abbreviations and Acronyms
EBUS-FNA ¼ endobronchial ultrasound-guided
fine-needle aspiration
EUS ¼ endoscopic ultrasound
FN ¼ false negative
FP ¼ false positive
MLN ¼ mediastinal lymph node
NPV ¼ negative predictive value
NSCLC ¼ non–small cell lung cancer
ROSE ¼ rapid on-site evaluation
TN ¼ true negative
TP ¼ true positive
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diagnostic biopsy results by EBUS-FNA who underwent a confirmatory
procedure that sampled different MLN stations than those biopsied by
EBUS-FNA, because we would not be able to verify our EBUS-FNA find-
ings in these patients. We also excluded patients who underwent EBUS-
FNA of peribronchial masses. We collected the following information:
(1) indications for EBUS-FNA; (2) immediate cytology (rapid on-site eval-
uation [ROSE]), permanent cytology, and histology findings; (3) number of
MLN stations sampled, (4) short-axis diameter of sampled MLNs; (5) pro-
cedural time (defined as time elapsed between repositioning of the endotra-
cheal tube by the surgeon at the beginning of the procedure and immediate
cytopathologic diagnosis [ROSE]); and (6) additional confirmatory and
therapeutic procedures performed in the same anesthesia setting.
Endobronchial Ultrasound-Guided Fine-Needle
Aspiration
Our EBUS-FNA procedures were performed by 1 board-certified tho-
racic surgeon (R.S.A.) as previously described.2,15 Briefly, we perform
the procedure under general anesthesia and sample each MLN station 3
times (10–15 passes per sample).
Rapid On-Site Evaluation
We rely on ROSE for intraoperative decision making because our 3 cy-
topathologists are experienced with transbronchial FNA specimens. As de-
termined by the cytologist, the adequacy of cytology specimens is defined
by the presence of lymphocytes; 40 lymphocytes per high-powered field
or clusters of pigmented macrophages are strong predictors of an adequate
cytology specimen.18 The absence of lymphocytes has a significant negative
impact of the NPV of EBUS-FNA specimens slides (2 per sample), and all
excess material is saved in formalin for further cytologic interpretation.19
Statistical Analysis
For overall diagnosis (based on ROSE), a true positive (TP) result was
defined by the presence of any abnormal MLN pathology, whether benign
(eg, granuloma or hyperplasia) or malignant. A true negative (TN) result
was defined by the presence of a normal (and adequate) sample. If the sample
was nondiagnostic or deemed normal after completion of EBUS-FNA but
then abnormal after a confirmatory procedure, we defined the result as a false
negative (FN). If the sample was deemed abnormal after completion of EBUS-
FNA but then normal after a confirmatory procedure, we defined the result as
a false positive (FP). All calculations were made on a per patient basis.
For cancer diagnosis (based on ROSE), we defined a TP by the presence
of malignant MLN pathology and a TN by a normal or benign (and ade-
quate) sample and confirmation of nonmalignant diagnosis on surgical bi-The Journal of Thoracic and Caopsy of the same MLN station. If the sample was nondiagnostic or
deemed normal after completion of EBUS-FNA but then malignant after
a confirmatory procedure, we defined the result as an FN. If the sample
was deemed malignant after completion of EBUS-FNA but then normal af-
ter a confirmatory procedure, we defined the result as an FP.
For benign diagnosis (based on ROSE), we defined a TP by the presence
of benign pathology (ie, granuloma, hyperplasia) and confirmation of that
specific pathologic diagnosis with a surgical biopsy of the same MLN sta-
tion. We defined a TN by a normal sample and confirmation of normal MLN
histology on surgical biopsy of the same MLN station. If the sample was
nondiagnostic or deemed normal after completion of EBUS-FNA but
then pathologic (ie, granuloma, hyperplasia) after a confirmatory procedure,
we defined the result as an FN. If the sample was deemed pathologic (ie,
granuloma, hyperplasia) after completion of EBUS-FNA but then normal
after a confirmatory procedure, we defined the result as an FP.
We used the standard definitions of sensitivity (TP/[TPþFN]), specific-
ity (TN/[TNþFP]), positive predictive value (PPV) (TP/[TPþFP]), NPV
(TN/[TNþFN]), and accuracy ([TPþTN]/[TPþTNþFPþFN]).
To analyze our data, we used SAS version 9.1 (SAS Institute Inc, Cary,
NC). We report descriptive statistics as the median (range in parentheses) or
mean  standard deviation.
RESULTS
Patients
During the study period, 192 patients underwent EBUS-
FNA, and 98 patients met our inclusion criteria. Indications
for EBUS-FNA were mediastinal lymphadenopathy
(56.1%) and thoracic malignancy staging (43.9%). On en-
doscopic evaluation, the median short-axis MLN diameter
was 11 mm (range, 3–30 mm). Table 1 lists the final patho-
logic diagnoses.
Performance Measures
We found a higher sensitivity, NPV, and accuracy for ma-
lignant MLN pathology than for benign pathology (Table 2).
ROSE findings were identical to permanent cytology find-
ings in 92 patients (94.8%) (Table 3). Of the 33 patients
with NSCLC, 14 (14.4%) underwent EBUS-FNA to diag-
nose recurrence; 19 patients (19.6%) underwent initial stag-
ing EBUS-FNA before any form of therapy or underwent
restaging after neoadjuvant therapy. In these 19 patients,
the mean number of central MLN stations sampled was
3.0  0.9. One patient with NSCLC had an FN ROSE in
an N1 (11R) lymph node.
Efficiency of Patient Care
The total procedure time (including pathologic diagnosis)
was recorded in 31 patients (mean, 46.5  20.5 minutes);
the procedure time per MLN station was 20.8 10.5 minutes.
We performed 88 additional procedures in 49 patients (50%)
in the same anesthesia setting as EBUS-FNA (Table 4). Be-
cause a malignant diagnosis was made on ROSE, 53 patients
(54%) avoided a more invasive diagnostic procedure.
DISCUSSION
Our report demonstrates that thoracic surgeons can (1) ac-
curately use EBUS-FNA, (2) follow appropriate oncologicrdiovascular Surgery c Volume 139, Number 3 579
FIGURE 1. Patients included in and excluded from the study. EBUS,
Endobronchial ultrasound.
TABLE 2. Summary of cases of rapid on-site evaluation and
permanent cytology discrepancy
ROSE results Final cytology
Nondiagnostic NSCLC
Necrotic lymph node NSCLC
Nondiagnostic Granuloma
Benign lymph node Sarcoid
Necrotic lymph node NSCLC
Total: 5 (5.2%)
NSCLC, Non–small cell lung cancer; ROSE, rapid on-site evaluation.
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FNA, and (3) perform additional procedures at the same
time as EBUS-FNA to streamline patient care.Accurate Use of Endobronchial Ultrasound-Guided
Fine-Needle Aspiration
At the University of Minnesota, EBUS-FNA had an over-
all sensitivity of 88.9%, a specificity of 96%, an PPV of
98.5%, an NPV of 75%, and an accuracy of 90.7%. Our se-
ries is unique, because 43.9% of our patients had a benign
final pathologic diagnosis, and these performance measuresTABLE 1. Final pathologic diagnoses
No. Percent
Diagnosis n ¼ 98 %
Benign pathology
Normal 25 25.5
Granuloma 15 15.3
Hyperplasia 3 3.1
Primary lung cancer
NSCLC 33 33.7
SCLC 5 5.1
Other malignancies
Esophageal 4 4.1
Lymphoma 3 3.1
Breast 2 2.0
Uterine 1 1.0
Transitional cell 1 1.0
Melanoma 1 1.0
Colorectal 1 1.0
Duodenal 1 1.0
Renal cell 1 1.0
Thyroid 1 1.0
Mesothelioma 1 1.0
NSCLC, Non–small cell lung cancer; SCLC, small cell lung cancer.
580 The Journal of Thoracic and Cardiovascular Surgreflect the use of EBUS-FNA as a diagnostic tool for indica-
tions other than lung cancer. No data published to date have
used surgical biopsy to verify the performance of EBUS-
FNA in benign disease.17,18 For benign disease, the sensitiv-
ity was lower than the sensitivity for malignant disease
(72.2% vs 87.9%). Nonetheless, we now first evaluate all
patients with suspected benign mediastinal lymphadenopa-
thy with EBUS-FNA; if ROSE demonstrates benign pathol-
ogy (ie, granuloma, hyperplasia) and the clinical suspicion
for a malignant process is low, we do not perform any other
confirmatory procedure. However, if the sample is negative
or nondiagnostic, we will obtain a surgical biopsy in the
same anesthesia setting.
EBUS-FNA in patients with cancer had a sensitivity of
87.9%, an NPV of 84.4%, and an accuracy of 91.7%. These
values compare favorably with the published values for
EBUS-FNA in lung cancer.1-7 In addition, our values also
compare well with the results of mediastinoscopy in patients
with cancer.8-14,19 The NPV of EBUS-FNA in cancer is still
somewhat lower than that of mediastinoscopy. In patients
with suspected malignancy, a negative EBUS-FNA sample
must be interpreted in the context of the pretest probability
of cancer in the sampled MLN. We strongly encourage veri-
fication of a negative ROSE result if the clinician has any sus-
picion that the MLN is potentially positive for malignancy.
We observed 1 FP result in a patient with squamous cell
cancer of the left distal mainstem bronchus. This patient un-
derwent an EBUS-FNA of MLN station 7 through the right
mainstem bronchus in an attempt to minimize the possibility
of contamination with dysplastic bronchial cells; the cytol-
ogy result was positive. Unique clinical circumstances led
the patient to undergo a left pneumonectomy. At the timeTABLE 3. Summary of predictive measures for endobronchial
ultrasound-guided fine-needle aspiration based on immediate
pathology
Overall Cancer diagnosis Benign diagnosis
Sensitivity (%) 88.9 87.9 72.2
Specificity (%) 96.0 97.4 95.8
PPV (%) 98.5 98.1 92.8
NPV (%) 75.0 84.4 82.1
Accuracy (%) 90.7 91.7 85.7
PPV, Positive predictive value; NPV, negative predictive value.
ery c March 2010
TABLE 4. Summary of additional procedures performed at the time
of endobronchial ultrasound-guided fine-needle aspiration
Procedure No. performed %
Diagnostic
Mediastinoscopy 25 26.3
EUS 15 15.8
MLND (open or
thoracoscopic)
14 14.3
Therapeutic
Lobectomy 13 13.7
Pulmonary wedge resection 8 8.4
Other
EGD 4 4.2
PEG 4 4.2
Port-a-catheter placement 4 4.2
Pleurodesis 1 1.0
Total additional procedures: 88
EUS, Endoscopic ultrasound (esophageal); MLND, mediastinal lymph node dissec-
tion; EGD, esophagogastroduodenoscopy; PEG, percutaneous endoscopic gastro-
stomy.
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right mainstem bronchus requiring a carinal resection. Surgi-
cal pathology of the subcarinal lymph nodes was negative.
We concluded that the presence of carcinoma in situ at the
proximal right mainstem bronchus contaminated our
EBSU-FNA specimen, leading to an FP result. Conse-
quently, we now sample MLN station 7 via esophageal en-
doscopic ultrasound (EUS) in patients with central
squamous cell cancers or if any suspicion exists that an FP
result is a possibility. To our knowledge, this is the first re-
port of an FP EBUS-FNA result in the literature.
Appropriate Oncologic Staging With Endobronchial
Ultrasound-Guided Fine-Needle Aspiration
At least 3 N2 MLN stations (4R, 4L, and 7) should be
sampled when staging potentially operable NSCLC. To
our knowledge, this is the first report in the literature indicat-
ing that 3 MLN stations per patient can be routinely sampled
with EBUS-FNA (previous publications sampled only an
average of 1.5 MLN stations per patient), indicating that
EBUS-FNA can be used as a staging tool while adhering
to oncologic principles.7,17 We also emphasize that relying
on ultrasonographic criteria alone to determine whether an
MLN is benign or malignant is fraught with errors, as evi-
denced by the experience with EUS.20 FNA is recommended
even for benign-appearing MLNs.
Effective Patient Care
Thoracic surgeons who perform EBUS-FNA have the
unique opportunity to streamline patient care because of
their ability to perform any necessary additional diagnostic
or therapeutic procedure in the same anesthesia setting.
We performed at least 1 additional procedure in 50% of
our patients at the same time as EBUS-FNA. ConfirmatoryThe Journal of Thoracic and Casurgical biopsies (eg, mediastinoscopy, thoracoscopy) are
performed immediately, if necessary. In addition, we will
perform EUS in the same setting, commonly with the
EBUS bronchoscope, under the following circumstances:
(1) failed sampling or a nondiagnostic sample of MLN sta-
tions 2R, 2L, 4L, or 7; (2) concern of a potential FP sample
in patients with diffuse airway metaplasia or dysplasia; or (3)
sampling of MLN stations 8 and 9, left adrenal gland, or liver
lesions if indicated.
We often perform EBUS-FNA as a staging procedure in
the same setting as a pulmonary resection. On the basis of
our last 31 procedures, an average EBUS-FNA takes 46.5
minutes from start to official ROSE reading by the cytolo-
gist; this is not an unreasonable amount of time if combined
with a pulmonary resection. Of note, the procedural time of
a mediastinoscopy, from the start of positioning to skin clo-
sure, is shorter than that for EBUS-FNA; however, the time
to process a frozen section is longer than the time required
for ROSE. Preliminary observations at our the University
of Minnesota suggest that an expeditious mediastinoscopy
saves approximately 10 minutes when compared with EBUS-
FNA (unpublished data, Rafael Andrade, MD, 2009).
Finally, a thoracic surgeon can perform other therapeutic
or palliative interventions (eg, intravenous port placement,
gastrostomy tube placement, pleurodesis) in the same setting
as EBUS-FNA.Limitations
Our study is retrospective and included only patients with
malignant EBUS-FNA findings or benign disease confirmed
by a surgical biopsy; we acknowledge the potential for selec-
tion bias given our study design. In addition, the focused ex-
perience of a single operator and a small group of expert
pathologists who are always available for ROSE will not uni-
versally be reproducible in clinical practice. The best way to
determine the diagnostic performance of EBUS-FNA will be
to carry out a prospective, multi-institutional study that will
directly compare EBUS-FNA with surgical biopsy.Recommendations
We suggest that thoracic surgeons who want to start a suc-
cessful EBUS-FNA program work in close relationship with
pathologists. Our recommendations to minimize diagnostic
inaccuracies are as follows:
1. Patients with suspected or confirmed malignant disease:
An FN result in a patient with malignant disease can have
serious clinical repercussions; for this reason, a novice
EBUS-FNA team should initially confirm every nonma-
lignant result with a surgical biopsy. Experienced EBUS-
FNA teams should corroborate nonmalignant cytology
results in accordance with the clinical situation.
2. Patients with suspected benign disease: The evaluation
of patients with clinically suspected benign diseaserdiovascular Surgery c Volume 139, Number 3 581
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FNA team’s experience. We recommend initial verifica-
tion of every benign or nondiagnostic cytology finding
with a surgical biopsy, and then the EBUS-FNA team
will have accurately determined the diagnostic perfor-
mance of EBUS-FNA for benign disease on its own.CONCLUSIONS
We conclude that it is imperative for thoracic surgeons to
become facile with EBUS-FNA for several reasons: (1) to
accurately use EBUS-FNA as a diagnostic tool in patients
with thoracic diseases, (2) to perform EBUS-FNA following
appropriate oncologic principles (ie, proper sampling of
standard MLN stations); and (3) to streamline patient care,
because thoracic surgeons have the ability to perform addi-
tional interventions at the same time as EBUS-FNA.References
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Dr Hiran Fernando (Boston, Mass). Dr Andrade, a common
clinical challenge for thoracic surgeons is accurately diagnosing
a patient with a specific benign pathology, such as sarcoidosis,
and often these patients will have a number of diagnostic proce-
dures before referral to a thoracic surgeon, including transbron-
chial needle aspiration or fine-needle aspiration. You describe
success rates for benign and malignant diagnoses, and you separate
these in Table 3 in your article. You mention that you have a lower
sensitivity for a benign diagnosis of 72.7% versus 87.9% for ma-
lignancy. Do you mean that this 72.7% was simply to make a be-
nign rather than a cancer diagnosis or does this sensitivity refer to
actually making a specific benign diagnosis, such as sarcoid or his-
toplasmosis? If you suspect that a patient up front has a benign di-
agnosis in a lymph node station that would be accessible by
mediastinoscopy where you would get the whole lymph node,
would you recommend mediastinoscopy for that patient or an ini-
tial EBUS on the basis of your results, and what would be your rea-
soning for your approach?
Dr Andrade. In terms of the first question, the way we broke the
benign analysis down was by presumptive diagnosis. That’s what
the calculation reflects. Can you repeat your second question
once again, please?
Dr Fernando. If you have a specific benign cause, for instance,
if a pulmonologist sends you a patient with a possible diagnosis of
sarcoidosis, would you recommend EBUS as an initial approach or
would you go straight to mediastinoscopy where you can get lymph
node architecture?
Dr Andrade. A lot of it depends on your pretest probability. The
main thing you want to avoid is missing a malignancy. If a patient
has a clinical picture suggestive of sarcoid, and EBUS-FNA cytol-
ogy demonstrates sarcoid that is noncaseating granuloma, I will
stop there. However, all of my patients provide consent for media-
stinoscopy, and I tell them if there’s any doubt, we will proceed
with a mediastinoscopy.
Dr Fernando. So your initial approach would still be EBUS for
those patients?
Dr Andrade. Yes.
Dr Fernando. Another question going on from that is, when you
have a patient who has a known diagnosis of cancer but who does
not have MLN enlargement by computed tomography or positron
emission tomography abnormalities, do you recommend EBUS
in those patients with clinically normal lymph nodes on the basisery c March 2010
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patients?
Dr Andrade. I think that decision depends on the surgeon. In
my practice, a patient with a normal mediastinum and early-stage
cancer will undergo an EBUS. If I obtain good samples on
ROSE intraoperatively, I will then proceed with a lobectomy. How-
ever, I would not encourage surgeons who are not experienced with
EBUS to do this until they have passed their learning curve.
Dr Fernando. You still have a fairly significant NPV for media-
stinoscopy, so why perform the EBUS if you’re going to then per-
form a thoracoscopy? Are you going to then go on to perform
a mediastinoscopy after the EBUS?
Dr Andrade. There are 2 points here. One, are you going to
stage the mediastinum or not. That’s another point of discussion.
By assuming that one decides to stage the mediastinum, and on
the basis of our experience with nearly 200 EBUS procedures, I
can now confidently say that if the clinical stage is I and the
ROSE demonstrates a good sample with benign lymphocytes, I
do not confirm it with mediastinoscopy. However, if I have any
shred of doubt, I will do a mediastinoscopy.
Dr Thomas D’Amico (Durham, NC). That was a good study,
well designed and well performed. I have 2 questions. Did you
say if you had any complications from your 200 EBUS-FNAs?
Were there any significant complications?
Dr Andrade. No, I didn’t say. If you look at all of them, we had
3 patients out of almost 200 who stayed overnight for respiratory
decompensation. That has been the only complication we have
had so far.
Dr D’Amico. I think the 2 most important findings, other than
how well your NPV is, are that you have twice as many lymph
nodes per station, as in much of the literature, for which you are
to be congratulated, and that you trust ROSE, which a lot of other
practitioners have given up on. How have you perfected ROSE to
the point that you can trust it to do a secondary procedure?
Dr Andrade. We are fortunate to have outstanding pathologists
at our institution. I think that is the only reason we can get away
with that. They have extensive experience with transbronchial nee-
dle aspiration biopsy. A cytologist has to have specific experience
in this to be able to interpret these samples reliably.
Dr F. Detterbeck (New Haven, CT). First, I think it’s more im-
portant to calculate things by patient and not by node. You artifi-The Journal of Thoracic and Cacially make your numbers look better when you calculate it by
node, and I think you really have to do it by patient. Second, I think
you really can’t make a statement about the usefulness of this for
staging lung cancer when you’re also mixing in people and just try-
ing to get a diagnosis of mediastinal tissue, such as for sarcoid. I
think you have to separate that. Third, this is an important contribu-
tion. I think it is an important fact that you have done this carefully.
It makes a difference whether somebody is invested in a technique
and does it well. You have sampled a lot of nodes and you have
been careful to look at your results, and I can tell you that I think
EBUS looks good in some literature reports, but in some places
where it’s done, where people stick 1 node and then get out and
don’t do a good job, they are not going to get nearly as good results.
Thoracic surgeons who have a vested interest in appropriately stag-
ing the mediastinum are more likely to do a good job, such as you
have done.
Dr Andrade. Thank you.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). In that one
case with an FP, is it your practice to change your needle for
each lymph node station? Also, did you look in retrospect at
what the cause was of that FP reading? Were the cytopatholo-
gists reading the contamination of cells from the airway on the
way in?
Dr Andrade. The first answer is yes, we do change our needle.
If we first diagnose a malignant lymph node, we do not use that
needle again. In response to the FP case, this particular patient
had a distal left main stem squamous cell cancer. I purposefully
biopsied the subcarinal lymph nodes through the right main stem
bronchus to avoid any potential contamination. Eventually, he
underwent surgery and required a carinal pneumonectomy because
there was a carcinoma in situ extending all the way across the
carina into the proximal right main stem. What I do now if I have
any suspicion of contaminations is to biopsy level 7 via EUS or
mediastinoscopy.
Dr Nasser Altorki (New York, NY). Rafael, I have a quick ques-
tion for you. Do you have any experience with diagnosis of N1 sta-
tions?
Dr Andrade. Yes. We didn’t mention it here. We do sample N1
lymph nodes. We don’t do it as a staging procedure. We do it more
in patients with a diagnosis of probable lung cancer and we’re sam-
pling to get a tissue diagnosis.rdiovascular Surgery c Volume 139, Number 3 583
